Akero Therapeutics ((AKRO)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Akero Therapeutics is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis.’ The study aims to assess the safety and efficacy of Efruxifermin (EFX) in treating patients with NASH/MASH and fibrosis, a significant health concern due to its potential to progress to cirrhosis and liver failure.
The intervention being tested is Efruxifermin, administered via subcutaneous injection. It is designed to improve liver health in patients with NASH/MASH by reducing liver fat and fibrosis.
This interventional study is randomized with a parallel assignment model, involving a quadruple masking approach to ensure unbiased results. The primary purpose is treatment, focusing on the therapeutic effects of Efruxifermin.
The study began on December 1, 2023, with primary completion expected by August 2025. The last update was submitted on August 18, 2025, indicating ongoing progress.
The outcome of this study could significantly influence Akero Therapeutics’ stock performance, given the high unmet need for effective NASH treatments. Success could position Akero as a leader in this space, potentially impacting investor sentiment positively. Competitors in the NASH treatment market will be closely monitoring these developments.
The study is currently recruiting, with further details available on the ClinicalTrials portal.